Assessment of Carfilzomib Treatment Response in Lung Transplant Recipients With Antibody-mediated Rejection

Data supporting the use of carfilzomib (CFZ) for treatment of antibody-mediated rejection (AMR) in lung transplantation in combination with plasmapheresis and intravenous immunoglobulin suggest positive outcomes through donor-specific antibody (DSA) depletion or conversion to noncomplement-activatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Christine, Pierce, Brett J., Nguyen, Duc T., Graviss, Edward A., Huang, Howard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Lung Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969244/
https://www.ncbi.nlm.nih.gov/pubmed/33748409
http://dx.doi.org/10.1097/TXD.0000000000001131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969244/
https://www.ncbi.nlm.nih.gov/pubmed/33748409
http://dx.doi.org/10.1097/TXD.0000000000001131

Ejemplares similares